nctId,briefTitle,overallStatus,studyType,phases,leadSponsor,conditions,ctgov_url,has_resultsSection,pass_interventional,pass_phase23
NCT00799903,"LPL100601, A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects With Chronic Coronary Heart Disease to Compare the Incidence of Major Adverse Cardiovascular Events (MACE)",COMPLETED,INTERVENTIONAL,PHASE3,GlaxoSmithKline,Atherosclerosis,https://clinicaltrials.gov/study/NCT00799903,1,1,1
NCT01000727,A Clinical Outcomes Study of Darapladib Versus Placebo in Subjects Following Acute Coronary Syndrome to Compare the Incidence of Major Adverse Cardiovascular Events (MACE).,COMPLETED,INTERVENTIONAL,PHASE3,GlaxoSmithKline,Acute Coronary Syndrome,https://clinicaltrials.gov/study/NCT01000727,1,1,1
NCT01687998,Assessment of Clinical Effects of Cholesteryl Ester Transfer Protein Inhibition With Evacetrapib in Patients at a High-Risk for Vascular Outcomes,TERMINATED,INTERVENTIONAL,PHASE3,Eli Lilly and Company,Cardiovascular Diseases,https://clinicaltrials.gov/study/NCT01687998,1,1,1
NCT01130246,VISTA-16 Trial: Evaluation of the Safety and Efficacy of Short-Term A-002 Treatment in Subjects With Acute Coronary Syndromes,TERMINATED,INTERVENTIONAL,PHASE3,Anthera Pharmaceuticals,Acute Coronary Syndrome,https://clinicaltrials.gov/study/NCT01130246,0,1,1
NCT00658515,"A Randomized, Double-blind, Placebo-controlled Study Assessing the Effect of RO4607381 on Cardiovascular Mortality and Morbidity in Clinically Stable Patients With a Recent Acute Coronary Syndrome",COMPLETED,INTERVENTIONAL,PHASE3,Hoffmann-La Roche,Coronary Heart Disease,https://clinicaltrials.gov/study/NCT00658515,1,1,1
NCT00134264,"Phase 3 Multi Center, Double Blind, Randomized, Parallel Group Evaluation Of The Fixed Combination Torcetrapib/Atorvastatin, Administered Orally, Once Daily (Qd), Compared With Atorvastatin Alone, On The Occurrence Of Major Cardiovascular Events In Subjects With Coronary Heart Disease Or Risk Equivalents",TERMINATED,INTERVENTIONAL,PHASE3,Pfizer,Coronary Disease | Diabetes Mellitus,https://clinicaltrials.gov/study/NCT00134264,0,1,1
NCT02145468,A Clinical Outcomes Study to Compare the Incidence of Major Adverse Cardiovascular Events in Subjects Presenting With Acute Coronary Syndrome Treated With Losmapimod Compared to Placebo (PM1116197) LosmApimod To Inhibit p38 MAP Kinase as a TherapeUtic Target and moDify Outcomes After an Acute Coronary syndromE (LATITUDE)-TIMI 60.,COMPLETED,INTERVENTIONAL,PHASE3,GlaxoSmithKline,Acute Coronary Syndrome,https://clinicaltrials.gov/study/NCT02145468,1,1,1
NCT00185146,Effect of Pactimibe on the Progression of Atherosclerosis as Measured by 2-D and 3-D Carotid Ultrasound,COMPLETED,INTERVENTIONAL,PHASE2,Sankyo Pharma Gmbh,Atherosclerosis,https://clinicaltrials.gov/study/NCT00185146,0,1,1
NCT01975376,"Phase 3 Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel Group Evaluation Of The Efficacy, Safety, And Tolerability Of Bococizumab (Pf-04950615) In Reducing The Occurrence Of Major Cardiovascular Events In High Risk Subjects.",TERMINATED,INTERVENTIONAL,PHASE3,Pfizer,Cardiovascular Disease,https://clinicaltrials.gov/study/NCT01975376,1,1,1
